Generally, TGF-β1 activates the ALK5 type I receptor (which phosphorylates SMAD2/3) as well as noncanonical (e.g., Src kinase, EGFR, JAK/STAT, P53) pathways that jointly drive cancer progression [38, 39]. The gene discussed is EGFR; the disease is cancer.